{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:52:47Z","timestamp":1791377567563,"version":"4.3.2"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2210751"],"award-info":[{"award-number":["W81XWH2210751"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2210247"],"award-info":[{"award-number":["W81XWH2210247"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM008042"],"award-info":[{"award-number":["T32GM008042"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM152342"],"award-info":[{"award-number":["T32GM152342"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005595","name":"University of California","doi-asserted-by":"publisher","award":["P30CA016042"],"award-info":[{"award-number":["P30CA016042"]}],"id":[{"id":"10.13039\/100005595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["R01CA270108"],"award-info":[{"award-number":["R01CA270108"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["U2CCA271894"],"award-info":[{"award-number":["U2CCA271894"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007185","name":"University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.euo.2025.10.013","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:59:30Z","timestamp":1762610370000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8222-3117","authenticated-orcid":false,"given":"Raag","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aydin","family":"Pooli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Sisk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Elashoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Rettig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.10.013_b0005","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.10.013_b0010","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.euo.2025.10.013_b0015","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1158\/0008-5472.CAN-11-3132","article-title":"Pten loss and RAS\/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem\/progenitor cells","volume":"72","author":"Mulholland","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2025.10.013_b0020","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1158\/0008-5472.CAN-11-3004","article-title":"Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy","volume":"72","author":"Sun","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2025.10.013_b0025","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/nm.2236","article-title":"Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance","volume":"16","author":"Tanaka","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2025.10.013_b0030","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-07-1263","article-title":"A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer","volume":"13","author":"Gravdal","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.10.013_b0035","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.3390\/cancers15082309","article-title":"Epithelial-to-mesenchymal transition-related markers in prostate cancer: from bench to bedside","volume":"15","author":"Gogola","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2025.10.013_b0040","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nrc.2017.118","article-title":"EMT in cancer","volume":"18","author":"Brabletz","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euo.2025.10.013_b0045","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers10020052","article-title":"The epithelial-to-mesenchymal transition in cancer","volume":"10","author":"Roche","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2025.10.013_b0050","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10555-013-9481-1","article-title":"Src signaling pathways in prostate cancer","volume":"33","author":"Varkaris","year":"2014","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.euo.2025.10.013_b0055","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1158\/0008-5472.CAN-10-1605","article-title":"Invasive prostate carcinoma driven by c-Src and androgen receptor synergy","volume":"71","author":"Cai","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2025.10.013_b0060","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1073\/pnas.1103904108","article-title":"Differential transformation capacity of Src family kinases during the initiation of prostate cancer","volume":"108","author":"Cai","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.euo.2025.10.013_b0065","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1073\/pnas.1120985109","article-title":"Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression","volume":"109","author":"Drake","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.euo.2025.10.013_b0070","doi-asserted-by":"crossref","first-page":"D766","DOI":"10.1093\/nar\/gky955","article-title":"GENCODE reference annotation for the human and mouse genomes","volume":"47","author":"Frankish","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.euo.2025.10.013_b0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.euo.2025.10.013_b0080","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.euo.2025.10.013_b0085","unstructured":"Babraham Bioinformatics. FastQC: a quality control tool for high throughput sequence data. https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/."},{"key":"10.1016\/j.euo.2025.10.013_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109665","article-title":"Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer","volume":"36","author":"Tewari","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.euo.2025.10.013_b0095","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12859-019-2610-2","article-title":"BPG: seamless, automated and interactive visualization of scientific data","volume":"20","author":"P\u2019ng","year":"2019","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.euo.2025.10.013_b0100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1741-7015-8-18","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"8","author":"Schulz","year":"2010","journal-title":"BMC Med"},{"key":"10.1016\/j.euo.2025.10.013_b0105","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3389\/fonc.2019.00586","article-title":"SRC and MEK co-inhibition synergistically enhances the anti-tumor effect in both non-small-cell lung cancer (NSCLC) and erlotinib-resistant NSCLC","volume":"9","author":"Yuan","year":"2019","journal-title":"Front Oncol"},{"issue":"Suppl","key":"10.1016\/j.euo.2025.10.013_b0110","volume":"37","author":"Taplin","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T02:50:05Z","timestamp":1763779805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125002871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":22,"alternative-id":["S2588931125002871"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.10.013","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}